Amping up T cells to target cancer
SMRTR summary
MIT researchers have developed a new mRNA-based vaccine adjuvant that dramatically boosts T-cell responses in cancer and infectious disease vaccines. In mouse studies, the adjuvant helped slow or eradicate multiple tumor types and produced T-cell responses 10 to 15 times stronger than standard covid and flu vaccines. The approach avoids the severe side effects linked to cytokine-based immune stimulation.
SMRTR provides this summary for quick context. The original article belongs to MIT Technology Review.
Read the original article